Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): update of the combined TEXT and SOFT trials - Regan, MM; Walley, BA; Fleming, GF (San Antonio Breast Cancer Symposium 2021, 2022)
et al.